In addition to the effect on diminishing intraglomerular hyperfiltration and hypertension, SGLT-2 inhibitors also demonstrate anti-inflammatory, antifibrotic, and protective effects against deregulation of extracellular matrix evidenced by a reduction in serum levels of TNF receptor 1, IL-6, matrix metalloproteinase 7, and fibronectin 1 [62]. The gene discussed is FN1; the disease is hypertensive disorder.